Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Terminated 2Recruiting 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Genitourinary 1

Conditions

Cardiotoxicity 2Breast Neoplasms 2Renal Insufficiency, Chronic 1Kidney Neoplasms 1Heart Failure 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 1282Specimen Handling 927Carboplatin 836Magnetic Resonance Spectroscopy 834Cyclophosphamide 807Cisplatin 735Nivolumab 680Paclitaxel 635Radiotherapy 617Gemcitabine 580Biopsy 559Bevacizumab 485Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 361Fluorouracil 357atezolizumab 350durvalumab 340Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 319Blood Specimen Collection 317Standard of Care 311Pemetrexed 307Ipilimumab 303Radiation 287

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
empagliflozin × 1 year × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

NCT03424005 2026-03-16

Morpheus-panBC

Hoffmann-La Roche

Phase 1/2 Recruiting
792 enrolled
Breast

Breast Neoplasms

NCT06818305 2025-12-11

EmFin-Nx

Jinling Hospital, China

Phase 2 Terminated
10 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Renal Insufficiency, Chronic

NCT05271162 2025-11-21

EMPACT

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 3 Recruiting
220 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡